Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sentinel Lymph Node Mapping vs Standard Lymph Node Dissection in Endometrial Cancer
NCT05646316Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Dec 2022
- Primary completion
- Oct 2026
- Countries
- 2
01
Overview
Phase 3, randomised trial (2 arms), sponsored by NRG Oncology. Primary endpoint: Incidence of patient-reported lower extremity limb dysfunction at 39 months. Started Dec 2022; status: recruiting.
Beyond the preview
Go deeper on NCT05646316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646316.